

CURRICULUM VITAE

Name	Tae-Hwan Kim
Place of Birth	Seoul, Korea
Office Address	Division of Rheumatology Hanyang University Hospital for Rheumatic Diseases 222-1 wangsimni-ro, Sungdong-ku, Seoul 04763, Korea Tel) 82-2-2290-9245 Fax) 82-2-2298-8231 E-mail) thkim@hanyang.ac.kr
Education	1982 – 1988 : MD degree from Hanyang University College of Medicine, Seoul, Korea 1992 – 1997 : Master degree from Hanyang University College of Medicine, Seoul, Korea 1997 – 1999 : Ph D degree form Korea University College of Medicine, Seoul, Korea
Academic Appointments	1997 – : Lecturer, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea 2002- : Assistant Professor 2007- : Associate Professor 2012- : professor
Career	1988 – 1989 : Internship, Hanyang University Hospital, Seoul, Korea 1989 – 1992 : Residency at Department of Internal Medicine, Hanyang University Hospital, Seoul, Korea 1995 – 1997 : Clinical Fellow at Rheumatism Center, Hanyang University Medical Center, Seoul, Korea 2002-2004 : Research Fellow at University of Toronto
Membership	Member of the Korean Internal Medicine Member of the Korean Rheumatism Association Member of the Korean Research Group of Collagen Diseases and Related disorders
Interest	Ankylosing spondylitis clinic, pathogenesis and genetics Spondylopathy

Publication

1. Kim HW, Kwon SR, Jung KH, Kim SK, Baek HJ, Seo MR, Bang SY, Lee HS, Suh CH, Jung JY, Son CN, Shim SC, Lee SH, Lee SG, Lee YA, Lee EY, **Kim TH**, Kim YG; Korean Society of Spondyloarthritis Research. Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. *PLoS One*. 2016 Apr 21;11(4):e0153816. doi: 10.1371/journal.pone.0153816. eCollection 2016.
2. Jo S, Wang SE, Lee YL, Kang S, Lee B, Han J, Sung IH, Park YS, Bae SC, **Kim TH**. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. **Arthritis Res Ther.** **2018 Jun 7;20(1):115**
3. Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. *Ann Rheum Dis*. 2018 Sep;77(9):1295-1302
4. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. *Lancet*. 2019 Dec 7;394(10214):2108-2117
5. Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group. Ixekizumab Treatment in Patients with Non-Radiographic Axial Spondyloarthritis: Results of a 52-Week, Randomised, Placebo-Controlled Trial. *Lancet*. 2020 Jan 4;395(10217):53-64
6. Lim DH, Lee EJ, Kwon OC, Hong S, Lee CK, Yoo B, Youn J, Kim TH, Kim YG.
7. Jo S, Yoon S, Lee SY, Kim SY, Park H, Han J, Choi SH, Han JS, Yang JH, Kim TH. DKK1 Induced by 1,25D3 Is Required for the Mineralization of Osteoblasts. *Cells*. 2020 Jan 17;9(1). pii: E236. doi: 10.3390/cells9010236.
8. Lee JK, Jo S, Lee YL, Park H, Song JS, Sung IH, Kim TH. Anterior cruciate ligament remnant cells have different potentials for cell differentiation based on their location. *Sci Rep*. 2020 Feb 20;10(1):3097. doi: 10.1038/s41598-020-60047-w.
9. Jo S, Lee EJ, Nam B, Kang J, Lee S, Youn J, Park YS, Kim YG, Kim TH. Effects of Dihydrotestosterone on Osteoblast Activity in Curdlan-Administered SKG Mice and Osteoprogenitor Cells in Patients With Ankylosing Spondylitis. *Arthritis Res Ther*. 2020 May 24;22(1):121
10. Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, Joo KB, Kim TH. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. *Ann Rheum Dis*(IF:16.102;Q1). 2020 Oct;79(10):1327-1332.
11. Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, Joo KB, Kim TH. Response to 'Correspondence on "Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing

- spondylitis: 18-year real-world evidence" by Zhanget al. *Ann Rheum Dis*(IF:16.102;Q1). 2020 Oct 1;annrheumdis-2020-218944. doi: 10.1136/annrheumdis-2020-218944. Online ahead of print.
12. Jo S, Won EJ, Kim MJ, Lee YJ, Jin SH, Park PR, Song HC, Kim J, Choi YD, Kim JY, Shim SC, Choi SH, Park YS, Kim TH, Kim TJ. STAT3 Phosphorylation Inhibition for Treating Inflammation and New Bone Formation in Ankylosing Spondylitis. *Rheumatology (Oxford)* . 2020 Nov 25;keaa846. doi:10.1093/rheumatology/keaa846. Online ahead of print.
 13. Song Y, Jo S, Chung JY, Oh Y, Yoon S, Lee YL, Kim SS, Yang JH, Jang K, Yang CS, Kim TH, Kim YH. RNA interference-mediated suppression of TNF- α converting enzyme as an alternative anti-TNF- α therapy for rheumatoid arthritis. *J Control Release* (IF: 7.727; **Q1**). 2021 Feb 10;330:1300-1312. doi: 10.1016/j.jconrel.2020.11.041. Epub 2020 Nov 24.
 14. Lee TH, Koo BS, Nam B, Oh JS, Park SY, Lee S, Joo KB, Kim TH. Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset. *Ther Adv Musculoskelet Dis*. 2020 Nov 28;12:1759720X20975912. doi: 10.1177/1759720X20975912. eCollection 2020.
 15. Koo BS, Kim TH. The role of ixekizumab in non-radiographic axial spondyloarthritis. *Ther Adv Musculoskelet Dis* (IF: 5.043; **Q1**) 2021 Jan 12;13:1759720X20986734. doi: 10.1177/1759720X20986734. eCollection 2021.